Efficacy and Safety of Switching from Topical Latanoprost to Bimatoprost in Patients with Normal-Tension Glaucoma

Abstract

Significant additional IOP lowering was achieved by switching to bimatoprost in Japanese patients with NTG with insufficient response to latanoprost. Bimatoprost treatment was safe and well tolerated.

Comparison between bimatoprost and latanoprost-timolol fixed combination for efficacy and safety after switching patients from latanoprost

“… 25 Our study, which is the first randomized prospective clinical trial of these two treatments in the Japanese population, showed that both treatments were effective in controlling IOP starting from baseline. It has also been reported that bimatoprost has a greater IOP-lowering effect than latanoprost, 12 – 15 and that LTFC reduces the IOP levels to a greater degree than latanoprost monotherapy 26 – 30 in both the Japanese population and in other races. We found similar results in our current study.…”

“…While it appears that bimatoprost has great potential with regard to its IOP-lowering effect, it has been reported to cause more conjunctival hyperemia than has been seen in patients treated with latanoprost 15 , 33 or LTFC. 23 , 24 In our study, we found that the conjunctival injection score at 12 weeks was higher in the bimatoprost group vs the LTFC group, which mirrors the results of the previous reports.…”

“… 12 Several studies have reported that bimatoprost exhibits a greater IOP-lowering effect than latanoprost 0.005% (Xalatan ® , Pfizer Inc, Tokyo, Japan). 12 – 15 Among the possible drug combinations that can be used when adding a second drug, utilization of a prostaglandin analog with a β-blocker has been shown to be one of the most effective and widely prescribed combinations. 16 In Japan, the fixed combination of latanoprost 0.005% and timolol maleate 0.5% (LTFC, Xalacom ® , Pfizer Inc) has recently become available.…”

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events

“…Bimatoprost ophthalmic solution 0.03% (bimatoprost) has been marketed in Japan since 2009. Sato et al8 applied latanoprost to NTG patients as a treatment of choice and then changed the treatment to bimatoprost; the authors reported the latter had a better effect.…”

Preservative-free fixed combination of bimatoprost and timolol in the evolution of compliance and treatment effectiveness in patients with primary open-angle glaucoma

“…В ходе метаанализа, включающего восемь рандомизированных контролируемых клинических исследований, включающих 1610 пациентов с первичной открытоугольной глаукомой (ПОУГ) и офтальмогипертензией (ОГ), биматопрост 0,03 % показал максимальную способность к снижению ВГД по сравнению с латанопростом и травопростом [16]. Важным является также то, что клинические исследования показали высокую эффективность и хорошую переносимость биматопроста при нормотензивной глаукоме [17], в том числе при недостаточной эффективности латанопроста [18], резистентность к которому при нормотензивной глаукоме довольно высока. В ряде исследований биматопрост показал высокую эффективность и безопасность и у пациентов с псевдоэксфолиативной глаукомой (ПЭГ), обеспечив достижение целевого давления у большинства пациентов [19].…”